The Protocole LLC

Based in the US, The Protocole LLC specializes in providing access to medical-grade peptides through a membership model, offering personalized wellness solutions designed to enhance health and longevity. Founded in 2026 and headquartered in New York, US, The Protocole LLC focuses on delivering clinical-grade peptide protocols. The company has secured funding through a SEED round, raising a total of USD 6. 00 mn, led by Rare Capital, with the most recent deal occurring on April 15, 2026.

The founder's history includes previous entrepreneurial ventures, although specific details are not available. The Protocole specializes in providing access to medical-grade peptides through an exclusive membership model aimed at individuals seeking enhanced wellness solutions. The company's core offerings include physician-formulated peptide protocols that address various health and wellness goals, such as muscle recovery, weight management, and cognitive support. Customers apply for membership to receive personalized protocol recommendations based on clinical credibility and optimized for individual health needs.

The peptides are sourced from FDA-registered U. S. pharmacies, ensuring high standards of purity, potency, and sterility. The Protocole serves a clientele focused on health optimization and longevity primarily in urban markets across the United States, where wellness and anti-aging trends are increasingly popular.

The Protocole operates on a subscription-based revenue model, charging a monthly fee of USD 60 for continued access to its services after an initial order. This structure allows clients to receive ongoing clinical support, priority refills, and access to member-only pricing on peptides, which are sold separately. The initial order includes a tailored protocol and clinical-grade peptides, with each vial typically starting at USD 200 and lasting approximately 4-6 weeks. The company’s revenue is generated through direct-to-consumer transactions, enabling The Protocole to foster long-term relationships with its customers, promoting continued usage of its products and services.

In April 2026, The Protocole LLC raised USD 6 mn in SEED funding led by Rare Capital. The company will utilize this funding to support its overall growth and further the development of its clinical-grade peptide platform. Future plans include the design and launch of new peptide products, with specific timelines yet to be announced, and an expansion into additional urban markets across the United States, aligning with the growing wellness trends.